Fikret I Atamdede, MD
Gynecological Oncology · Torrance
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 47 years
- Medical College of Wisconsin, 1979
Offices
1 location · Los Angeles Hematology-Oncology Medical Group · 51 clinicians in this group
Hospitals listed: Providence Little Company of Mary Med Ctr Torrance · Torrance Memorial Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Atamdede’s office at (310) 375-8446 to ask if they take your plan before you enroll.
California Medical Board record
Licence G56999 · Current
Licensed to practise in California · since 1986 · expires 2028-04-30 · University of Wisconsin Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Pacific Coast Surgical Center, LPAmbulatory Surgery Center · Torrance, CA.5 owner since 2008 · accredited by AAAHCAccreditation Renewed5 inspections, 4 with deficiencies · last 2024-09-10: Requirements Met
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Gynecologic Oncology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Little Company of Mary Med Ctr TorranceTorrance, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.472, Oct 2024 – Sep 2025
- Torrance Memorial Medical CenterTorrance, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 82% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.11 to 1.61), Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 15.79 (10.51 to 21.07) · 1,494 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.21 (0.72 to 1.71) · 9,154 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.328, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Little Company of Mary Med Ctr Torrance
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.472 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.09 (0.11 to 2.07) · 1,022 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.59 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 129.31 (75.73 to 182.88) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 353 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 361 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 495 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 3,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 5,786 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.06 to 0.45) · 5,832 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.21 (2.1 to 6.32) · 1,135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.81 (0.22 to 3.4) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.8 to 3.86) · 1,086 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.78 (2.28 to 15.28) · 389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.58 (1.19 to 7.98) · 377 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2 (0.51 to 3.49) · 247 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 0.93) · 4,918 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.892 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.225 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.363 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 283 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 709 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.5 · 149 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 428 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.8 · 369 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 551 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 59 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (8.9 to 15.5) · 642 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 331 cases | No different | Jan 2024 – Dec 2024 |
What patients said (414 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Torrance Memorial Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.11 to 1.61) | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 15.79 (10.51 to 21.07) · 1,494 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.21 (0.72 to 1.71) · 9,154 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.328 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.72) · 2,154 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.72 (128.91 to 214.54) · 121 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 176 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 766 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 806 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 608 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 7,587 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.28 (0.1 to 0.47) · 11,109 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.03 to 0.39) · 11,330 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.13 (2.41 to 5.85) · 2,964 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0.13 to 3.16) · 1,513 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.66 (1.3 to 4.01) · 2,802 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.24 (2.35 to 8.14) · 1,479 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 650 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2 · 962 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.023 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.646 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.259 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.658 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 1,578 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 21.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 900 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.9 · 800 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.1 · 1,223 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.3) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7 to 15) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 928 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 316 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.5 to 16.1) · 624 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 781 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,607 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$145,386
Medicare paid this office $145,386 for 106 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 59 | $9,270 | $101 |
| New patient visit (60+ min) | 37 | $6,478 | $175 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 40 | $1,695 | $42 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,649 | $103 |
| Complete ultrasound scan of pelvis | 15 | $1,522 | $95 |
See all 7 services
| Return visit (30+ min) | 59 | $9,270 | $101 |
| New patient visit (60+ min) | 37 | $6,478 | $175 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 40 | $1,695 | $42 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,649 | $103 |
| Complete ultrasound scan of pelvis | 15 | $1,522 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,183 | $108 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $741 | $49 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
106 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 35% · Health risk score 1.74. Above the middle of the specialty; the typical gynecological oncology clinician is at 1.53.
Conditions among them: High blood pressure 75% · Diabetes 39% · Cancer 35% · Depression 27% · Heart failure 25% · Chronic kidney disease 25% · Coronary heart disease 24% · Atrial fibrillation 20% · COPD 15%.
The office billed $772,186, Medicare allowed $184,525 and paid $145,386; for 14,668 services of 68 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 106 | 14,668 | 73 | 1.74 | $772,186 | $145,386 |
| 2023 | 133 | 11,275 | 72 | 1.38 | $1,081,637 | $263,562 |
| 2022 | 194 | 24,411 | 73 | 1.27 | $1,324,990 | $265,709 |
| 2021 | 178 | 57,327 | 74 | 1.37 | $1,511,514 | $263,133 |
| 2020 | 171 | 59,239 | 72 | 1.61 | $1,242,831 | $182,616 |
| 2019 | 198 | 69,703 | 73 | 1.55 | $1,610,148 | $239,706 |
| 2018 | 227 | 40,623 | 74 | 1.59 | $1,427,586 | $189,962 |
| 2017 | 231 | 69,381 | 74 | 1.72 | $1,979,342 | $316,259 |
| 2016 | 254 | 89,178 | 73 | 1.52 | $2,908,314 | $387,686 |
| 2015 | 239 | 83,991 | 72 | 1.69 | $3,065,867 | $413,536 |
| 2014 | 255 | 35,653 | 72 | 1.48 | $1,922,603 | $297,532 |
| 2013 | 255 | 25,331 | 72 | 1.46 | $2,312,933 | $329,756 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 93 | $12,641 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $7,651 | $114 |
| New patient visit (60+ min) | 24 | $4,102 | $171 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 51 | $2,186 | $43 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 11 | $1,706 | $26 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $1,547 | $103 |
| Complete ultrasound scan of pelvis | 15 | $1,484 | $93 |
| Injection of additional new drug or substance into vein | 11 | $1,161 | $14 |
| Short return visit (20+ min) | 15 | $1,084 | $68 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $682 | $49 |
2022: 16 services
| Return visit (30+ min) | 141 | $25,450 | $105 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $14,439 | $121 |
| New patient visit (60+ min) | 27 | $4,639 | $172 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $4,517 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 13 | $3,880 | $28 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 86 | $3,740 | $43 |
| Long return visit (40+ min) | 16 | $2,614 | $145 |
| Short return visit (20+ min) | 27 | $2,077 | $69 |
| Injection of additional new drug or substance into vein | 13 | $1,917 | $15 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 29 | $1,416 | $49 |
| Complete ultrasound scan of pelvis | 15 | $1,380 | $86 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $1,332 | $89 |
| Injection, paclitaxel, 1 mg | 11 | $1,010 | None |
| Injection, palonosetron hcl, 25 mcg | 12 | $761 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $129 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $51 | None |
2021: 18 services
| Return visit (30+ min) | 130 | $25,578 | $105 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $17,718 | $132 |
| New patient visit (60+ min) | 51 | $9,210 | $181 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $8,965 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $4,566 | $29 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 82 | $3,597 | $44 |
| Long return visit (40+ min) | 15 | $2,814 | $156 |
| Injection of additional new drug or substance into vein | 14 | $2,324 | $16 |
| Injection, palonosetron hcl, 25 mcg | 14 | $2,197 | None |
| Short return visit (20+ min) | 23 | $2,191 | $78 |
| Injection, paclitaxel, 1 mg | 12 | $2,111 | None |
| Complete ultrasound scan of pelvis | 14 | $1,846 | $103 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,620 | $108 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 32 | $1,582 | $49 |
| New patient visit (45+ min) | 11 | $1,478 | $134 |
| Injection, carboplatin, 50 mg | 12 | $1,122 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $215 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $65 | None |
2020: 14 services
| Administration of chemotherapy into vein, 1 hour or less | 14 | $21,608 | $126 |
| Return visit (30+ min) | 102 | $14,533 | $84 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $9,608 | $62 |
| New patient visit (60+ min) | 45 | $7,877 | $175 |
| Injection, palonosetron hcl, 25 mcg | 14 | $5,309 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $5,218 | $28 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 63 | $2,785 | $44 |
| Injection of additional new drug or substance into vein | 14 | $2,699 | $15 |
| Complete ultrasound scan of pelvis | 25 | $2,671 | $95 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $2,640 | $102 |
| Short return visit (20+ min) | 39 | $2,388 | $57 |
| Injection, carboplatin, 50 mg | 11 | $1,189 | None |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 20 | $971 | $49 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $248 | None |
2019: 17 services
| Administration of chemotherapy into vein, 1 hour or less | 20 | $26,240 | $127 |
| Return visit (30+ min) | 119 | $17,441 | $90 |
| Injection, palonosetron hcl, 25 mcg | 19 | $15,318 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 20 | $9,702 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $8,549 | $62 |
| New patient visit (60+ min) | 42 | $7,207 | $172 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 110 | $4,707 | $43 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 30 | $3,484 | $102 |
| Injection of additional new drug or substance into vein | 20 | $3,296 | $15 |
| Complete ultrasound scan of pelvis | 29 | $3,233 | $98 |
| Short return visit (20+ min) | 40 | $2,875 | $56 |
| Injection, paclitaxel, 1 mg | 15 | $2,371 | None |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 37 | $1,803 | $49 |
| Injection of drug or substance under skin or into muscle | 11 | $1,472 | $15 |
| Injection, carboplatin, 50 mg | 15 | $1,461 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $311 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $59 | None |
2018: 14 services
| Administration of chemotherapy into vein, 1 hour or less | 14 | $22,867 | $130 |
| Injection, palonosetron hcl, 25 mcg | 13 | $20,990 | None |
| Return visit (30+ min) | 122 | $16,020 | $89 |
| New patient visit (60+ min) | 64 | $11,417 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $10,915 | $28 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 41 | $5,068 | $106 |
| Complete ultrasound scan of pelvis | 41 | $4,815 | $100 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 104 | $4,317 | $42 |
| Short return visit (20+ min) | 55 | $3,706 | $60 |
| Injection of additional new drug or substance into vein | 14 | $2,892 | $16 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,247 | $49 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 11 | $2,191 | $199 |
| Long return visit (40+ min) | 11 | $1,390 | $126 |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $229 | None |
2017: 22 services
| Injection, palonosetron hcl, 25 mcg | 19 | $30,129 | None |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $22,477 | $122 |
| Return visit (30+ min) | 135 | $19,413 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 19 | $12,594 | $28 |
| New patient visit (60+ min) | 71 | $12,485 | $176 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $7,483 | $59 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 41 | $5,173 | $106 |
| Complete ultrasound scan of pelvis | 41 | $4,855 | $99 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 110 | $4,646 | $42 |
| Injection of additional new drug or substance into vein | 19 | $3,894 | $20 |
| Short return visit (20+ min) | 55 | $3,296 | $51 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 16 | $3,121 | $195 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 50 | $2,506 | $50 |
| Injection, paclitaxel, 1 mg | 12 | $2,008 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,895 | $172 |
| Infusion into a vein for hydration, each additional hour | 12 | $1,400 | $14 |
| Long return visit (40+ min) | 11 | $1,379 | $125 |
| Injection, carboplatin, 50 mg | 12 | $1,198 | None |
| Injection, ranitidine hydrochloride, 25 mg | 12 | $289 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 19 | $256 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $94 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $44 | None |
2016: 26 services
| Injection, palonosetron hcl, 25 mcg | 30 | $46,879 | None |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $40,064 | $120 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 30 | $21,548 | $27 |
| Return visit (30+ min) | 136 | $19,746 | $91 |
| New patient visit (60+ min) | 76 | $13,149 | $173 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $10,152 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 168 | $7,014 | $42 |
| Injection of additional new drug or substance into vein | 30 | $6,928 | $20 |
| Short return visit (20+ min) | 94 | $6,603 | $57 |
| Ct scan of abdomen and pelvis with contrast | 28 | $5,846 | $189 |
| Long return visit (40+ min) | 25 | $3,620 | $125 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 14 | $3,178 | $227 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 25 | $2,973 | $106 |
| Complete ultrasound scan of pelvis | 25 | $2,704 | $97 |
| Injection, paclitaxel, 1 mg | 18 | $2,677 | None |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 52 | $2,595 | $50 |
| Ct scan of chest with contrast | 24 | $2,054 | $79 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,888 | $172 |
| Injection, carboplatin, 50 mg | 20 | $1,844 | None |
| Infusion into a vein for hydration, each additional hour | 15 | $1,830 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,321 | $88 |
| Administration of chemotherapy into vein, each additional hour | 16 | $1,063 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 27 | $568 | None |
| Injection, ranitidine hydrochloride, 25 mg | 28 | $403 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $131 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $83 | None |
2015: 30 services
| Injection, palonosetron hcl, 25 mcg | 28 | $47,228 | None |
| Administration of chemotherapy into vein, 1 hour or less | 28 | $40,558 | $121 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 12 | $24,064 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 28 | $22,399 | $27 |
| Return visit (30+ min) | 150 | $20,409 | $86 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $13,050 | $56 |
| Ct scan of abdomen and pelvis with contrast | 50 | $12,524 | $193 |
| New patient visit (60+ min) | 48 | $8,004 | $167 |
| Long return visit (40+ min) | 51 | $7,611 | $123 |
| Injection, fosaprepitant, 1 mg | 13 | $7,117 | None |
| Injection of additional new drug or substance into vein | 28 | $6,767 | $20 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 109 | $4,509 | $41 |
| Ct scan of chest with contrast | 42 | $4,130 | $75 |
| Short return visit (20+ min) | 56 | $3,325 | $57 |
| Infusion into a vein for hydration, each additional hour | 16 | $2,922 | $13 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 54 | $2,668 | $49 |
| Complete ultrasound scan of pelvis | 24 | $2,519 | $97 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 24 | $2,380 | $92 |
| Injection, carboplatin, 50 mg | 20 | $2,347 | None |
| Injection, paclitaxel, 1 mg | 16 | $2,116 | None |
| Injection of drug or substance under skin or into muscle | 16 | $1,987 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,492 | $88 |
| Injection, cisplatin, powder or solution, 10 mg | 14 | $653 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $580 | None |
| Administration of chemotherapy into vein, each additional hour | 13 | $548 | $25 |
| Injection, ranitidine hydrochloride, 25 mg | 23 | $428 | None |
| Injection, mannitol, 25% in 50 ml | 14 | $227 | None |
| Injection, granisetron hydrochloride, 100 mcg | 11 | $203 | None |
| Infusion, normal saline solution , 1000 cc | 16 | $160 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $93 | None |
2014: 28 services
| Injection, palonosetron hcl, 25 mcg | 24 | $35,697 | None |
| Administration of chemotherapy into vein, 1 hour or less | 24 | $28,909 | $117 |
| Return visit (30+ min) | 173 | $25,780 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 24 | $15,568 | $26 |
| New patient visit (60+ min) | 76 | $13,121 | $173 |
| Ct scan of abdomen and pelvis with contrast | 39 | $12,890 | $198 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $9,835 | $55 |
| Long return visit (40+ min) | 64 | $9,224 | $117 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 154 | $6,292 | $41 |
| Ct scan of chest with contrast | 36 | $5,180 | $85 |
| Injection of additional new drug or substance into vein | 24 | $4,935 | $20 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 90 | $4,401 | $49 |
| Complete ultrasound scan of pelvis | 22 | $2,896 | $111 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 22 | $2,836 | $109 |
| Injection, paclitaxel, 30 mg | 16 | $2,521 | None |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 11 | $2,512 | $228 |
| Infusion into a vein for hydration, each additional hour | 13 | $2,360 | $13 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,207 | $170 |
| Injection, carboplatin, 50 mg | 17 | $1,538 | None |
| Ct scan of chest without contrast | 11 | $1,384 | $106 |
| Short return visit (20+ min) | 22 | $1,297 | $59 |
| Ct scan of abdomen and pelvis without contrast | 14 | $1,180 | $69 |
| Administration of chemotherapy into vein, each additional hour | 11 | $468 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $391 | None |
| Injection, ranitidine hydrochloride, 25 mg | 13 | $154 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $89 | None |
| Unclassified drugs | 12 | $67 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $62 | None |
2013: 24 services
| Administration of chemotherapy into vein, 1 hour or less | 26 | $38,215 | $127 |
| Injection, palonosetron hcl, 25 mcg | 25 | $31,885 | None |
| Return visit (30+ min) | 150 | $19,188 | $83 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 26 | $17,983 | $28 |
| Ct scan of abdomen and pelvis with contrast | 42 | $14,287 | $230 |
| Long return visit (40+ min) | 74 | $11,697 | $115 |
| New patient visit (60+ min) | 71 | $11,604 | $163 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $11,552 | $63 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 172 | $7,028 | $41 |
| Injection of additional new drug or substance into vein | 26 | $6,042 | $20 |
| Ct scan of chest with contrast | 36 | $4,675 | $95 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 90 | $4,474 | $50 |
| Complete ultrasound scan of pelvis | 27 | $3,462 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,635 | $165 |
| Injection, paclitaxel, 30 mg | 14 | $2,453 | None |
| Short return visit (20+ min) | 34 | $2,230 | $60 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 27 | $1,931 | $60 |
| Injection, carboplatin, 50 mg | 14 | $1,462 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $1,307 | $13 |
| Administration of chemotherapy into vein, each additional hour | 11 | $514 | $27 |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $402 | None |
| Unclassified drugs | 18 | $109 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $88 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $48 | None |
Medicaid work
$35,367 in 2024
Medicaid paid $35,367 for 596 billed services this clinician did in 2024, up to 36 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 251 | $17,096 |
| New patient visit (60+ min) | 148 | $15,591 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 197 | $2,680 |
| 2024 | 596 | 3 | 36 | $35,367 |
| 2023 | 727 | 4 | 42 | $45,211 |
| 2022 | 547 | 4 | 34 | $35,882 |
| 2021 | 638 | 6 | 29 | $44,968 |
| 2020 | 400 | 5 | 34 | $22,891 |
| 2019 | 516 | 5 | 27 | $25,544 |
| 2018 | 608 | 4 | 41 | $18,729 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 376 | $30,259 |
| New patient visit (60+ min) | 58 | $7,570 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 267 | $6,855 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 26 | $528 |
2022
| Return visit (30+ min) | 299 | $28,059 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 207 | $5,232 |
| New patient visit (60+ min) | 26 | $2,541 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $49 |
2021
| Return visit (30+ min) | 285 | $26,261 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 53 | $5,621 |
| New patient visit (60+ min) | 38 | $4,859 |
| Palonosetron hcl | 50 | $4,480 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 184 | $2,972 |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $775 |
2020
| Return visit (30+ min) | 232 | $16,104 |
| New patient visit (60+ min) | 29 | $3,393 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 110 | $2,297 |
| Short return visit (20+ min) | 15 | $586 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $510 |
2019
| Return visit (30+ min) | 265 | $17,343 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 201 | $4,064 |
| New patient visit (60+ min) | 24 | $3,057 |
| Short return visit (20+ min) | 13 | $618 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $463 |
2018
| Return visit (30+ min) | 292 | $12,459 |
| New patient visit (60+ min) | 69 | $3,988 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 210 | $1,942 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 37 | $340 |
Drugs they prescribed that Part D paid
$355,729
Pharmacies billed $355,729 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 18% of their Part D prescriptions (53 of 291) in 2024. Above the middle of the specialty; the typical gynecological oncology clinician is at 13%.
227 generic and fewer than 11 brand-name prescriptions · $355,729 in drug cost · 66 antibiotic prescriptions to 57 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zejula | 12 | $226,624 | $18,885 |
| Premarin | 23 | $9,844 | $428 |
| Estradiol (Twice Weekly) | 13 | $1,097 | $84 |
| Clobetasol Propionate | 20 | $515 | $26 |
| Prochlorperazine Maleate | 23 | $292 | $13 |
See all 8 drugs
| Zejula | 12 | $226,624 | $18,885 |
| Premarin | 23 | $9,844 | $428 |
| Estradiol (Twice Weekly) | 13 | $1,097 | $84 |
| Clobetasol Propionate | 20 | $515 | $26 |
| Prochlorperazine Maleate | 23 | $292 | $13 |
| Cephalexin | 47 | $188 | $4 |
| Oxycodone-Acetaminophen | 14 | $85 | $6 |
| Tramadol | 32 | $58 | $2 |
Year by year
| 2024 | 291 | 115 | 18% (53) | None | $355,729 |
| 2023 | 312 | 125 | 16% (49) | 17% | $85,252 |
| 2022 | 340 | 140 | 18% (60) | None | $312,097 |
| 2021 | 380 | 137 | 20% (76) | 15% | $363,606 |
| 2020 | 283 | 109 | 16% (46) | 20% | $472,819 |
| 2019 | 355 | 120 | 15% (53) | 17% | $262,389 |
| 2018 | 455 | 129 | 16% (73) | 20% | $337,712 |
| 2017 | 499 | 162 | 24% (120) | 17% | $150,079 |
| 2016 | 431 | 139 | 21% (89) | 19% | $103,737 |
| 2015 | 383 | 124 | 17% (66) | 19% | $47,182 |
| 2014 | 488 | 147 | 14% (67) | 20% | $27,933 |
| 2013 | 383 | 124 | 21% (80) | 21% | $17,448 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Myrbetriq | 24 | $15,359 | $640 |
| Premarin | 16 | $7,317 | $457 |
| Estradiol | 20 | $2,285 | $114 |
| Megestrol Acetate | 16 | $1,572 | $98 |
| Estradiol (Twice Weekly) | 15 | $1,091 | $73 |
| Clobetasol Propionate | 16 | $927 | $58 |
| Peg 3350-Electrolyte | 25 | $561 | $22 |
| Prochlorperazine Maleate | 16 | $290 | $18 |
| Cephalexin | 26 | $148 | $6 |
| Tramadol | 26 | $79 | $3 |
| Oxycodone-Acetaminophen | 12 | $69 | $6 |
2022: 8 drugs
| Premarin | 26 | $11,141 | $429 |
| Clobetasol Propionate | 20 | $3,480 | $174 |
| Estradiol | 17 | $1,362 | $80 |
| Megestrol Acetate | 14 | $821 | $59 |
| Prochlorperazine Maleate | 23 | $542 | $24 |
| Cephalexin | 44 | $257 | $6 |
| Tramadol | 37 | $103 | $3 |
| Hydrocodone-Acetaminophen | 12 | $90 | $8 |
2021: 10 drugs
| Lynparza | 13 | $188,605 | $14,508 |
| Premarin | 20 | $8,397 | $420 |
| Estradiol | 15 | $3,073 | $205 |
| Clobetasol Propionate | 16 | $2,205 | $138 |
| Prochlorperazine Maleate | 31 | $432 | $14 |
| Dexamethasone | 17 | $423 | $25 |
| Hydrocodone-Acetaminophen | 23 | $181 | $8 |
| Cephalexin | 38 | $167 | $4 |
| Tramadol | 41 | $66 | $2 |
| Famotidine | 15 | $45 | $3 |
2020: 9 drugs
| Lenvima | 12 | $231,453 | $19,288 |
| Lynparza | 13 | $187,410 | $14,416 |
| Premarin | 15 | $6,691 | $446 |
| Megestrol Acetate | 16 | $788 | $49 |
| Prochlorperazine Maleate | 28 | $388 | $14 |
| Cephalexin | 25 | $134 | $5 |
| Hydrocodone-Acetaminophen | 13 | $74 | $6 |
| Tramadol | 29 | $66 | $2 |
| Sulfamethoxazole-Trimethoprim | 12 | $27 | $2 |
2019: 11 drugs
| Lynparza | 12 | $169,766 | $14,147 |
| Premarin | 11 | $4,857 | $442 |
| Estradiol | 16 | $3,461 | $216 |
| Prochlorperazine Maleate | 37 | $886 | $24 |
| Megestrol Acetate | 15 | $557 | $37 |
| Dexamethasone | 14 | $189 | $14 |
| Cephalexin | 24 | $170 | $7 |
| Hydrocodone-Acetaminophen | 20 | $141 | $7 |
| Pantoprazole | 18 | $125 | $7 |
| Temazepam | 13 | $105 | $8 |
| Tramadol | 27 | $72 | $3 |
2018: 12 drugs
| Lynparza | 14 | $201,066 | $14,362 |
| Zejula | 15 | $98,984 | $6,599 |
| Premarin | 33 | $12,499 | $379 |
| Yuvafem | 24 | $4,428 | $185 |
| Paroxetine Mesylate | 11 | $1,526 | $139 |
| Clobetasol Propionate | 13 | $1,193 | $92 |
| Megestrol Acetate | 11 | $398 | $36 |
| Hydrocodone-Acetaminophen | 41 | $361 | $9 |
| Prochlorperazine Maleate | 28 | $249 | $9 |
| Cephalexin | 22 | $148 | $7 |
| Potassium Chloride | 11 | $120 | $11 |
| Tramadol | 24 | $112 | $5 |
2017: 12 drugs
| Premarin | 19 | $6,606 | $348 |
| Estrace | 17 | $4,868 | $286 |
| Brisdelle | 11 | $1,986 | $181 |
| Clobetasol Propionate | 17 | $1,362 | $80 |
| Megestrol Acetate | 15 | $926 | $62 |
| Ondansetron Odt | 11 | $498 | $45 |
| Hydrocodone-Acetaminophen | 47 | $404 | $9 |
| Cephalexin | 39 | $299 | $8 |
| Prochlorperazine Maleate | 33 | $298 | $9 |
| Oxycodone-Acetaminophen | 19 | $214 | $11 |
| Ciprofloxacin | 19 | $165 | $9 |
| Tramadol | 32 | $130 | $4 |
2016: 12 drugs
| Clobetasol Propionate | 29 | $5,212 | $180 |
| Vagifem | 14 | $3,532 | $252 |
| Brisdelle | 11 | $1,919 | $174 |
| Megestrol Acetate | 19 | $884 | $47 |
| Hydrocodone-Acetaminophen | 54 | $634 | $12 |
| Prochlorperazine Maleate | 42 | $407 | $10 |
| Oxycodone-Acetaminophen | 19 | $348 | $18 |
| Fluconazole | 17 | $132 | $8 |
| Cephalexin | 22 | $130 | $6 |
| Ciprofloxacin | 15 | $122 | $8 |
| Lorazepam | 18 | $76 | $4 |
| Metoclopramide | 12 | $33 | $3 |
2015: 13 drugs
| Vagifem | 16 | $2,936 | $183 |
| Clobetasol Propionate | 17 | $2,682 | $158 |
| Oxybutynin Chloride Er | 13 | $636 | $49 |
| Hydrocodone-Acetaminophen | 44 | $526 | $12 |
| Prochlorperazine Maleate | 31 | $273 | $9 |
| Oxycodone-Acetaminophen | 12 | $265 | $22 |
| Dexamethasone | 15 | $173 | $12 |
| Cephalexin | 23 | $160 | $7 |
| Megestrol Acetate | 11 | $148 | $13 |
| Lorazepam | 19 | $89 | $5 |
| Ciprofloxacin | 16 | $88 | $5 |
| Lactulose | 12 | $59 | $5 |
| Ranitidine | 11 | $43 | $4 |
2014: 14 drugs
| Toviaz | 13 | $5,906 | $454 |
| Vagifem | 30 | $3,408 | $114 |
| Emend | 12 | $2,864 | $239 |
| Clobetasol Propionate | 40 | $1,751 | $44 |
| Oxybutynin Chloride Er | 16 | $942 | $59 |
| Megestrol Acetate | 29 | $702 | $24 |
| Hydrocodone-Acetaminophen | 56 | $646 | $12 |
| Ondansetron | 11 | $354 | $32 |
| Prochlorperazine Maleate | 35 | $322 | $9 |
| Cephalexin | 27 | $179 | $7 |
| Ciprofloxacin | 19 | $137 | $7 |
| Dexamethasone | 27 | $115 | $4 |
| Fluconazole | 14 | $106 | $8 |
| Ranitidine | 27 | $89 | $3 |
2013: 12 drugs
| Vagifem | 22 | $2,241 | $102 |
| Premarin | 14 | $2,180 | $156 |
| Megestrol Acetate | 20 | $1,026 | $51 |
| Oxybutynin Chloride Er | 14 | $1,004 | $72 |
| Hydrocodone-Acetaminophen | 62 | $606 | $10 |
| Gabapentin | 16 | $267 | $17 |
| Prochlorperazine Maleate | 24 | $248 | $10 |
| Ciprofloxacin | 20 | $119 | $6 |
| Cephalexin | 20 | $114 | $6 |
| Zolpidem | 13 | $83 | $6 |
| Dexamethasone | 14 | $47 | $3 |
| Ranitidine | 12 | $38 | $3 |
Money from drug and device companies
$596 in 2025
| 2025 | 12 | 17 | None | $596 |
| 2024 | 16 | 41 | None | $1,386 |
| 2023 | 16 | 35 | None | $2,431 |
| 2022 | 15 | 51 | None | $2,250 |
| 2021 | 19 | 53 | None | $1,943 |
| 2020 | 16 | 45 | None | $1,186 |
| 2019 | 21 | 82 | None | $3,397 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Caris MPI | Mi Cancer Seek | $165 | 1 payment
|
| Abbvie | Elahere | $83 | 3 payments
|
| Baxter Healthcare | Perclot | $64 | 2 payments
|
| Sumitomo Pharma America | Myfembree | $47 | 2 payments
|
| GlaxoSmithKline | Jemperli | $47 | 2 payments
|
| Boston Scientific | Bulkamid | $35 | 1 payment
|
See all 17 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-19 | Lynparza | $17 |
| Sumitomo Pharma America | Meals · 2025-11-06 | Myfembree | $20 |
| Sumitomo Pharma America | Meals · 2025-10-29 | Myfembree | $27 |
| Boston Scientific | Meals · 2025-10-02 | Bulkamid | $35 |
| Merck Sharp & Dohme | Meals · 2025-09-25 | Keytruda | $34 |
| Baxter Healthcare | Meals · 2025-08-14 | Perclot | $33 |
| Caris MPI | Meals · 2025-08-07 | Mi Cancer Seek | $165 |
| Pfizer | Meals · 2025-07-30 | Tivdak | $22 |
| Eisai | Meals · 2025-07-23 | Lenvima | $26 |
| Abbvie | Meals · 2025-06-02 | Elahere | $30 |
| Tempus AI | Meals · 2025-05-19 | Xt Cdx | $30 |
| Daiichi Sankyo | Meals · 2025-05-15 | Enhertu | $27 |
| Abbvie | Meals · 2025-04-03 | Elahere | $25 |
| GlaxoSmithKline | Meals · 2025-03-21 | Jemperli | $18 |
| GlaxoSmithKline | Meals · 2025-02-24 | Jemperli | $29 |
| Baxter Healthcare | Meals · 2025-02-18 | Perclot | $31 |
| Abbvie | Meals · 2025-02-06 | Elahere | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,386
| GlaxoSmithKline | Jemperli | $240 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $232 | 6 payments
|
| Medtronic | Ligasure | $198 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $130 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $109 | 1 payment
|
| Pfizer | Lorbrena | $99 | 1 payment
|
| Abbvie | Elahere | $77 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $52 | 2 payments
|
| Eisai | Lenvima | $49 | 2 payments
|
| Urgo Medical North America | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap | $48 | 1 payment
|
| Integra LifeSciences | Codman Certas | $31 | 1 payment
|
| Baxter Healthcare | Perclot | $29 | 1 payment
|
| ImmunoGen | Elahere | $28 | 1 payment
|
| Boston Scientific | Upsylon | $25 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Akynzeo | $21 | 1 payment
|
| Conmed | Airseal | $19 | 1 payment
|
2023: $2,431
| Intuitive Surgical | Da Vinci Surgical System | $1,089 | 3 payments
|
| Myriad Genetic Laboratories | Myrisk | $363 | 3 payments
|
| Medtronic | Sonicision | $312 | 2 payments
|
| GlaxoSmithKline | Zejula | $156 | 9 payments
|
| Seagen | Tukysa | $114 | 1 payment
|
| Eisai | Lenvima | $74 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $74 | 3 payments
|
| ImmunoGen | Elahere | $47 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $41 | 2 payments
|
| Minerva Surgical | None | $29 | 1 payment
|
| Integra LifeSciences | Biofix | $27 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $25 | 1 payment
|
| Boston Scientific | Upsylon | $23 | 1 payment
|
| Amneal Pharmaceuticals | Avastin | $22 | 1 payment
|
| Smith+Nephew | Stravix | $21 | 1 payment
|
| Ethicon US | Echelon; Endopath | $16 | 1 payment
|
2022: $2,250
| New Wave Endo-Surgical | None | $464 | 1 payment
|
| GlaxoSmithKline | Zejula | $459 | 21 payments
|
| Medtronic | Ligasure | $428 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $257 | 8 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $247 | 2 payments
|
| Seagen | Tukysa | $115 | 1 payment
|
| CooperSurgical | Supercut Hysterectomy Scissors | $41 | 1 payment
|
| Memic Innovative Surgery | Anovo Surgical System | $39 | 1 payment
|
| Baxter Healthcare | Tisseel | $34 | 1 payment
|
| Ethicon US | Vistaseal | $32 | 2 payments
|
| Integra LifeSciences | Codman Certas | $31 | 1 payment
|
| Myovant Sciences | Myfembree | $28 | 1 payment
|
| Boston Scientific | Upsylon | $27 | 1 payment
|
| Abbvie | Oriahnn | $27 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $22 | 1 payment
|
2021: $1,943
| AstraZeneca Pharmaceuticals LP | Lynparza | $285 | 8 payments
|
| Biom'Up France SAS | Hemoblast Bellows | $272 | 4 payments
|
| Coloplast | Altis | $258 | 4 payments
|
| Medtronic | Ligasure | $216 | 3 payments
|
| GlaxoSmithKline | Zejula | $158 | 8 payments
|
| AbbVie | Orilissa | $150 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $99 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $92 | 1 payment
|
| Baxter Healthcare | Tisseel | $90 | 1 payment
|
| Gynesonics | Sonata Sonography-Guided Transcervical Fibroid Ablation System | $78 | 1 payment
|
| Musculoskeletal Transplant Foundation | None | $49 | 2 payments
|
| DySIS Medical | Dysis Ultra | $44 | 1 payment
|
| Eisai | Lenvima | $40 | 2 payments
|
| Olympus America | Thunderbeat 5 Mm,35 Cm,Front-Actuated Grip Type S | $28 | 1 payment
|
| Heron Therapeutics | Sustol | $24 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $21 | 1 payment
|
| Ethicon US | Vistaseal | $15 | 1 payment
|
| Seagen | None | $13 | 1 payment
|
| Trevena | Olinvyk | $12 | 1 payment
|
2020: $1,186
| GlaxoSmithKline | Zejula | $190 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $181 | 8 payments
|
| Eisai | Lenvima | $156 | 9 payments
|
| Allergan | Strattice | $129 | 1 payment
|
| Seagen | Tukysa | $125 | 1 payment
|
| AbbVie | Orilissa | $73 | 4 payments
|
| Myriad Genetic Laboratories | Mychoice Cdx | $56 | 2 payments
|
| Baxter Healthcare | Tisseel | $55 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $45 | 3 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $42 | 1 payment
|
| Ethicon US | Ethicon Endo-Surgery Curved Intraluminal Stapler | $31 | 2 payments
|
| Acell | None | $27 | 1 payment
|
| Coloplast | Pelvic Floor Repair | $25 | 1 payment
|
| Foundation Medicine | Foundationone | $23 | 1 payment
|
| Biom'Up France SAS | Hemoblast Bellows | $18 | 1 payment
|
| Clovis Oncology | Rubraca | $10 | 1 payment
|
2019: $3,397
| Covidien LP | Ligasure | $807 | 9 payments
|
| AbbVie | Orilissa | $429 | 13 payments
|
| Baxter Healthcare | Tisseel | $349 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $329 | 9 payments
|
| Tesaro | Zejula | $222 | 6 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $208 | 2 payments
|
| Clovis Oncology | Rubraca | $183 | 11 payments
|
| Coloplast | Altis | $159 | 3 payments
|
| Pacira Pharmaceuticals | Exparel | $125 | 1 payment
|
| Acell | None | $107 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Akynzeo | $98 | 5 payments
|
| Boston Scientific | Xenform | $65 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $55 | 3 payments
|
| Ethicon US | Surgicel Powder | $54 | 3 payments
|
| Genentech USA | Avastin | $47 | 2 payments
|
| Eisai | Lenvima | $44 | 2 payments
|
| Amgen | Mvasi | $39 | 2 payments
|
| Avanos Medical | On-Q* Pump and Accessories | $37 | 1 payment
|
| Mylan Institutional | Fulphila | $14 | 1 payment
|
| Agiliti Surgical | None | $14 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $12 | 1 payment
|
Professional record
- NPI
- 1578502480
- Licence
- CA G56999California G56999: Current · expires 2028-04-30
- Trained
- Medical College of Wisconsin, 1979 · 47 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X)
- Mailing address
- 23600 Telo Ave Ste 250, Torrance, CA, 90505
- NPI first listed
- 2006-06-06
- NPI last updated
- 2024-11-12
- NPI record certified
- 2024-11-12
This is when the NPI record was last certified, not a medical board exam.